@article{e56a54a6ed1c4d458676e3cb8ee2f638,
title = "MDM2 inhibitors in the search for an optimized neovascular age-related macular degeneration treatment",
keywords = "Nutlin-3, angiogenesis, apoptosis, human double minute-2, macular degeneration, murine double minute-2, p53",
author = "{Kon Graversen}, Veronica and Chavala, {Sai H.}",
note = "Funding Information: The authors were supported by a Research to Prevent Blindness Career Development Award, a Foundation Fighting Blindness Career Development Award and an unrestricted Research to Prevent Blindness departmental grant. SH Chavala filed patent application no. 61/386,808, {\textquoteleft} MDM2 inhibitors for treatment of ocular conditions,{\textquoteright} in September 2010. SH Chavala is also the founder of Serrata LLC, a start-up company that plans to commercialize novel treatments for ocular disease. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.",
year = "2014",
month = oct,
day = "1",
doi = "10.1586/17469899.2014.952225",
language = "English",
volume = "9",
pages = "355--359",
journal = "Expert Review of Ophthalmology",
issn = "1746-9899",
publisher = "Taylor and Francis Ltd.",
number = "5",
}